Moreover, high TIMP1 after chemotherapy is connected with shorter OS in patients with ovarian cancer [38]. Furthermore, TIMP1 was independently related to the time to progression, and OS in patients with metastatic CRC receiving chemotherapy [39]. Here, TIMP1 is linked to ovarian cancer.